Cardiff Oncology (CRDF)
(Delayed Data from NSDQ)
$3.48 USD
+0.09 (2.65%)
Updated May 13, 2024 04:00 PM ET
After-Market: $3.49 +0.01 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.48 USD
+0.09 (2.65%)
Updated May 13, 2024 04:00 PM ET
After-Market: $3.49 +0.01 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 21.24% and 9.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 0.00% and 43.33%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Cardiff Oncology (CRDF) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiff Oncology (CRDF) Stock Jumps 7%: Will It Continue to Soar?
by Zacks Equity Research
Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -13.33% and 4.62%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.
Are Options Traders Betting on a Big Move in Cardiff Oncology (CRDF) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.
Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 0.00% and -4.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Cardiff Oncology (CRDF): Can Its 10.3% Jump Turn into More Strength?
by Zacks Equity Research
Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Rising P/E: An Overlooked Strategy to Pick Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Cardiff Oncology (CRDF) Stock Jumps 11.3%: Will It Continue to Soar?
by Zacks Equity Research
Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Cardiff Oncology (CRDF) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.
Implied Volatility Surging for Cardiff Oncology (CRDF) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.